Abstract
We read the study by Niesert et al in a recent edition of the American Journal of Cardiology. The investigators present the first clinical evidence on the use of novel oral anticoagulants (NOACs) in adult congenital heart disease (ACHD). In their study, 55 patients with congenital heart disease were started on NOACs. Median follow-up was 6 months and during this period only one NOAC therapy was stopped as a result of bleeding. 1 Niesert A.C. Pujol C. Engelhardt A. Lummert E. Schön P. Braun S. Ewert P. Kaemmerer H. OP-047 initial experience on the use of novel oral anticoagulants (NOAC) in adults with congenital heart disease. Am J Cardiol. 2015; 115: S21 Abstract Full Text Full Text PDF PubMed Google Scholar OP-047 Initial Experience on the Use of Novel Oral Anticoagulants (NOAC) in Adults with Congenital Heart DiseaseAmerican Journal of CardiologyVol. 115PreviewNowadays, most patients with Congenital Heart Disease survive to adulthood. Numerous adults with Congenital Heart Disease (ACHD) are prone to thromboembolic events. A study from our institution showed that 22 % of 821 ACHD were on oral anticoagulation1. Full-Text PDF
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
